Regeneron Pharmaceuticals IncREGN

REGN current price
$828.42+3.64%

Capital at risk.

1W
+0.81%
1M
-18.38%
3M
-28.72%
6M
-16.14%
1Y
+3.64%
MAX
+106.60%
About Regeneron Pharmaceuticals Inc
Ticker
info
REGN
Trading on
info
NASDAQ
ISIN
info
US75886F1075
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Leonard S. Schleifer M.D., Ph.D.
Headquarters
info
777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Employees
info
14,165
Website
info
regeneron.com
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Metrics
BasicAdvanced
Market cap
info
$91B
P/E ratio
info
20.49
EPS
info
$40.43
Dividend Yield
info
0.00%
Beta
info
0.14
Forward P/E ratio
info
18.38
EBIDTA
info
$4.6B
Ex dividend date
info
-
Price & volume
Market cap
info
$91B
Average daily volume
info
0.8M
90-day return
info
-28.72%
30-day return
info
-18.38%
7-day return
info
0.81%
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
20.49
Forward P/E
info
18.38
PEG ratio
info
1.23
Trailing P/E
info
20.49
Price to sales
info
6.57
Price to book
info
3.1
Earnings
EPS
info
$40.43
EPS estimate (current quarter)
info
$11.69
EPS estimate (next quarter)
info
$11.77
EBITDA
info
$4.6B
Revenues (TTM)
info
$13.8B
Revenues per share (TTM)
info
$128.69
Technicals
Beta
info
0.14
52-week High
info
$1,211.20
52-week Low
info
$784.96
50-day moving average
info
$1,021.70
200-day moving average
info
$1,010.30
Short ratio
info
2.45
Short %
info
1.64%
Management effectiveness
ROE (TTM)
info
17.17%
ROA (TTM)
info
7.41%
Profit margin
info
33.61%
Gross profit margin
info
$7.02B
Operating margin
info
33.43%
Growth
Quarterly earnings growth (YoY)
info
29.80%
Quarterly revenue growth (YoY)
info
10.60%
Share stats
Outstanding Shares
info
108M
Float
info
103M
Insiders %
info
1.56%
Institutions %
info
91.00%
Analyst Insights & forecasts
info

72% Buy

20% Hold

8% Sell

Based on information from 25 analysts.

Average price target

info
$1,098.79
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$11.86
$10.73
10.53%
Q4 • 23Beat
$9.55
$10.09
5.35%
Q1 • 24Beat
$11.56
$10.61
8.95%
Q2 • 24Beat
$12.46
$11.69
6.59%
Q3 • 24Beat
-
$11.38
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$3.55B
$1.43B
40.38%
Q2 • 24
$3.72B
$1.34B
36.03%
Q3 • 24
4.89%
6.40%
10.77%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$36.1B
$7.88B
21.84%
Q2 • 24
$37.4B
$8.12B
21.68%
Q3 • 24
3.76%
2.98%
0.75%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$354M
$-557M
$-478M
$143M
Q2 • 24
$1.29B
$-574M
$-634M
$1.11B
Q3 • 24
264.75%
3.09%
32.61%
674.00%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Greed

+1.5

0.59

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Regeneron Pharmaceuticals Inc share?
Collapse

Regeneron Pharmaceuticals Inc shares are currently traded for $828.42 per share.

How many shares does Regeneron Pharmaceuticals Inc have?
Collapse

Regeneron Pharmaceuticals Inc currently has 108M shares.

Does Regeneron Pharmaceuticals Inc pay dividends?
Collapse

No, Regeneron Pharmaceuticals Inc doesn't pay dividends.

What is Regeneron Pharmaceuticals Inc 52 week high?
Collapse

Regeneron Pharmaceuticals Inc 52 week high is $1,211.20.

What is Regeneron Pharmaceuticals Inc 52 week low?
Collapse

Regeneron Pharmaceuticals Inc 52 week low is $784.96.

What is the 200-day moving average of Regeneron Pharmaceuticals Inc?
Collapse

Regeneron Pharmaceuticals Inc 200-day moving average is $1,010.30.

Who is Regeneron Pharmaceuticals Inc CEO?
Collapse

The CEO of Regeneron Pharmaceuticals Inc is Dr. Leonard S. Schleifer M.D., Ph.D..

How many employees Regeneron Pharmaceuticals Inc has?
Collapse

Regeneron Pharmaceuticals Inc has 14,165 employees.

What is the market cap of Regeneron Pharmaceuticals Inc?
Collapse

The market cap of Regeneron Pharmaceuticals Inc is $91B.

What is the P/E of Regeneron Pharmaceuticals Inc?
Collapse

The current P/E of Regeneron Pharmaceuticals Inc is 20.49.

What is the EPS of Regeneron Pharmaceuticals Inc?
Collapse

The EPS of Regeneron Pharmaceuticals Inc is $40.43.

What is the PEG Ratio of Regeneron Pharmaceuticals Inc?
Collapse

The PEG Ration of Regeneron Pharmaceuticals Inc is 1.23.

What do analysts say about Regeneron Pharmaceuticals Inc?
Collapse

According to the analysts Regeneron Pharmaceuticals Inc is considered a buy.